[Ip-health] [Invite to Oxfam Brown Bag] Leahy Legislation to Ensure Access to University Innovations

[Robynn Sturm]

This is a multi-part message in MIME format.
--
--
[ Picked text/plain from multipart/alternative ]


Oxfam invites you to a Brown Bag Lunch:



Access to University-Developed Drugs in Low-Income Countries:

 A Legislative Solution?



Presentation by Universities Allied for Essential Medicines



Thursday, October 26th, 11:30-12:30
1100 15th St., NW, Suite 600





For five years, students across North America have been calling on their
universities to make the life-saving drugs discovered in campus laboratorie=
s
available in the developing world.  Recently a chorus of prominent voices
have joined their cause by signing on to the Philadelphia Consensus
Statement (See attached doc and full list of signatories below).  Yet
Universities have failed to act on this issue uniquely within their power.



In light of their inaction, Senator Patrick Leahy (D-VT) introduced the
Public Research in the Public Interest Act of 2006, which would require
humanitarian licensing of essential medicines as a condition for receipt of
federal research funding. The mandated humanitarian licensing terms would
allow generic manufacturers in the United States or abroad to supply drugs
developed at federally-funded institutions in eligible low- and
middle-income countries at affordable prices. (Copy of the bill attached).




UAEM will present a brief overview of why universities have a critical role
to play in delivering affordable medicines to the developing world, how
S.4040 proposes to address that problem, and the expected impact of the bil=
l
both on and off the Hill.



We encourage all to attend.  If you would like to join us, please RSVP your
name, title, organization and contact information to robynn.sturm@yale.edu.



=3D=3D



List of Initial Signatories to the Philadelphia Consensus Statement

Individuals
Zackie Achmat, Founder and Chairman, Treatment Action Campaign
Marcia Angell, Former Editor of the New England Journal of Medicine
Jerry Avorn, Professor of Medicine, Harvard Medical School
Dean Baker, Co-Director, Center for Economic and Policy Research
Solomon Benatar, Professor of Medicine, University of Cape Town; Foreign
Member, Institute of Medicine
Yochai Benkler, Professor of Law, Yale Law School
James Boyle, William Neal Reynolds Professor of Law, Duke University
Edwin Cameron, Justice, South African Supreme Court of Appeal
Art Caplan, Emmanuel and Robert Hart Professor of Bioethics, University of
Pennsylvania
Todd Capson, Associate Scientist, Smithsonian Tropical Research Institute
Arachu Castro, Director of the Institute of Health and Social Justice,
Partners in Health; and Assistant Professor of Social Medicine, Harvard
Medical School
Carlos Correa, Professor, University of Buenos Aires
Paul Davis, Director, U.S. Government Relations, Health GAP (Global Access
Project)
Nils Daulaire, President and CEO, Global Health Council
Paul Farmer, Presley Professor of Medical Anthropology, Harvard University
Howard Hiatt, Professor of Medicine, Harvard Medical School; former Dean of
the Harvard School of Public Health
Wim G.J. Hol, Professor, Biochemistry and Biological Structure, Investigato=
r
Howard Hughes Medical Institute, University of Washington
Peter Hotez, Director, Human Hookworm Vaccine Initiative
Jim Yong Kim, Fran=E7ois-Xavier Bagnoud Professor of Health and Human Right=
s,
Harvard University
Lawrence Lessig, Professor of Law at Stanford Law School
Stephen Lewis, UN Special Envoy for HIV/AIDS in Africa
Jamie Love, Director, Consumer Project on Technology
Peter Lurie, Deputy Director of Public Citizen's Health Research Group
J. Andrew McCammon, Investigator, Howard Hughes Medical Institute
Joseph E. Mayer Professor of Theoretical Chemistry, Professor of
Pharmacology, UC San Diego
Peter Menell, Professor of Law and Director, Berkeley Center for Law &
Technology
Michael Merson, Anna M R Lauder Professor of Public Health, Yale University
Jon F. Merz, Associate Professor, University of Pennsylvania School of
Medicine
Carol Mimura, Executive Director, UC Berkeley Office of Technology
Licensing, and Acting Assistant Vice Chancellor for Intellectual Property
and Industry Research Alliances
Beth Noveck, Director of the Institute for Information Law and Policy and
Associate Professor, New York Law School
Kevin Outterson, Professor of Law, West Virginia University
Bernard Pecoul, Executive Director of the Drugs for Neglected Diseases
Initiative
Thomas Pogge, Professor of Philosophy, Columbia University
Jonathan Quick, Former Director of Essential Drugs and Medicines Policy at
the World Health Organization and President and CEO of Management Sciences
for Health
Arti Rai, Professor of Law, Duke University
Pamela Samuelson, Professor of Law and Director, Berkeley Center for Law &
Technology
F.M. Scherer, Aetna Professor Emeritus of Government, Harvard University
Harold Simon, Professor of Family and Preventive Medicine, Chief of the
Division of International Health and Cross-cultural Medicine, UC San Diego
Sir John Sulston, Nobel Laureate in Medicine

Organizations
African Services Committee
American Medical Student Association
Canadian HIV/AIDS Legal Network
Community HIV/AIDS Mobilization Project (CHAMP)
Diverse Women For Diversity
Global AIDS Alliance
Global Health Council
International Peoples Health Council ( South Asia )
Initiative for Medicines, Access, and Knowledge (I-MAK)
Partners in Health
Research Foundation For Science Technology & Ecology
Stop HIV/AIDS in India Initiative (SHAII)
Student Campaign for Child Survival
Student Global AIDS Campaign

=3D=3D

UAEM is a coalition of over 25 student chapters across North America
dedicated to using university action to ameliorate the access-to-medicines
crisis in developing countries.  We have a two-fold mission: (1) to
determine how universities can help ensure that biomedical end products,
such as drugs, are made more accessible in developing countries and (2) to
faciilitate and increase the amount of research and development conducted o=
n
neglected diseases, or those diseases predominantly affecting people who ar=
e
too poor to constitute a market attractive to private-sector R&D investment=
.
Please see http://www.essentialmedicine.org/ for more information and
Contact Dave Chokshi (daveash@med.upenn.edu) if you wish to endorse the
Philadelphia Consensus Statement



--
[ S.4040.pdf of type application/pdf deleted ]
--
[ PhiladelphiaConsensusStatement.pdf of type application/pdf deleted ]
--
[ Public Research in the Public Interest Act Background Paper_b&w.doc of ty=
pe application/msword deleted ]
--